Amgen Inc (AMGN) announced positive results from Phase 3 trials for its eczema treatment, rocatinlimab, and myasthenia gravis treatment, Uplizna (inebilizumab). While rocatinlimab showed improvement over placebo, it fell short of existing competitors like Dupixent. Uplizna, however, exceeded expectations and has potential in the myasthenia gravis market due to its less frequent dosing and potential to reduce steroid use.